This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
CM-4307
DrugBank Accession Number
DB15414
Background

CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 467.85
Monoisotopic: 467.1051328
Chemical Formula
C21H16ClF3N4O3
Synonyms
  • DONAFENIB

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
41XGO0VS1U
CAS number
1130115-44-4
InChI Key
MLDQJTXFUGDVEO-FIBGUPNXSA-N
InChI
InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)/i1D3
IUPAC Name
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-(2H3)methylpyridine-2-carboxamide
SMILES
[2H]C([2H])([2H])NC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1

References

General References
Not Available
ChemSpider
23937167

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentChemotherapy Effects / HCC1
3CompletedTreatmentMetastatic Colorectal Cancer (CRC)1
3TerminatedTreatmentDifferentiated Thyroid Cancer (DTC)1
2CompletedTreatmentDifferentiated Thyroid Cancer (DTC)1
2Enrolling by InvitationTreatmentAdenocarcinoma of the Biliary Tract1
2Not Yet RecruitingPreventionAntimetabolites / Antineoplastic Agents / Carcinoma / Donafenib / Fluorouracil / Hepatocellular Carcinoma / Neoplasms, Gastrointestinal / Neoplasms, Hepatic / Oxaliplatin1
2Not Yet RecruitingTreatmentHepatocellular Carcinoma5
2Not Yet RecruitingTreatmentPancreatic Metastatic Cancer1
2Not Yet RecruitingTreatmentUnresectable Hepatocellular Carcinoma (HCC)1
2RecruitingTreatmentAnesthetics Adverse Reaction / Chemotherapy / Metastatic Cervical Carcinoma / Persistent Advanced Cervical Carcinoma / Recurrent Cervical Carcinoma / Survival Outcomes / Targeted Therapy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00171 mg/mLALOGPS
logP4.12ALOGPS
logP4.34Chemaxon
logS-5.4ALOGPS
pKa (Strongest Acidic)11.55Chemaxon
pKa (Strongest Basic)3.03Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area92.35 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity114.52 m3·mol-1Chemaxon
Polarizability41.23 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at May 20, 2019 15:27 / Updated at June 12, 2020 16:53